BLLN
$69.76
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance...
Recent News
BillionToOne Medicare Win Puts North Star Economics In Focus
BillionToOne (NasdaqGS:BLLN) has secured Medicare coverage for its North Star Select test. The company has rapidly expanded payer contracts, now reaching 250 million contracted lives in the U.S. This coverage and contract expansion mark a material operational milestone for BillionToOne’s diagnostic offering. BillionToOne focuses on molecular diagnostics, and North Star Select sits at the center of its clinical offering for physicians and patients. As payers continue to refine coverage for...
What Makes BillionToOne (BLLN) an Attractive Bet?
Baron Capital, an investment management company, released its Q4 2025 letter for its “Baron Global Opportunity Fund”. A copy of the letter can be downloaded here. Baron Global Opportunity Fund showcased a strong fourth quarter and an outstanding year. The Fund rose 6.5% (Institutional Shares) in Q4 compared to 3.3% return for the MSCI ACWI Index (the […]
BillionToOne Inc (BLLN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
BillionToOne Inc (BLLN) reports a remarkable 113% revenue increase and outlines ambitious growth plans for 2026 amidst competitive challenges.
Billiontoone Q4 Earnings Call Highlights
Billiontoone (NASDAQ:BLLN) reported fourth-quarter and full-year 2025 results that company leaders said reflected rapid growth, expanding margins, and continued investment in product development and market access. Management also raised its 2026 revenue outlook and pointed to multiple potential cata
BillionToOne (BLLN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.